These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25498771)

  • 1. Mapping from the Health Assessment Questionnaire to the EQ-5D: the impact of different algorithms on cost-effectiveness results.
    Pennington B; Davis S
    Value Health; 2014 Dec; 17(8):762-71. PubMed ID: 25498771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.
    Yuan Y; Trivedi D; Maclean R; Rosenblatt L
    J Med Econ; 2010 Mar; 13(1):33-41. PubMed ID: 20001596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gain in quality-adjusted life-years in patients with rheumatoid arthritis during 1 year of biological therapy: a prospective study in clinical practice.
    Linde L; Sørensen J; Østergaard M; Hetland ML
    J Rheumatol; 2013 Sep; 40(9):1479-86. PubMed ID: 23818719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for the treatment of rheumatoid arthritis.
    Bagust A; Boland A; Hockenhull J; Fleeman N; Greenhalgh J; Dundar Y; Proudlove C; Kennedy T; Moots R; Williamson P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():23-9. PubMed ID: 19804686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol.
    Ariza-Ariza R; Hernández-Cruz B; Carmona L; Dolores Ruiz-Montesinos M; Ballina J; Navarro-Sarabia F;
    Arthritis Rheum; 2006 Oct; 55(5):751-6. PubMed ID: 17013822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure.
    Merkesdal S; Kirchhoff T; Wolka D; Ladinek G; Kielhorn A; Rubbert-Roth A
    Eur J Health Econ; 2010 Feb; 11(1):95-104. PubMed ID: 19967426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK.
    Brennan A; Bansback N; Reynolds A; Conway P
    Rheumatology (Oxford); 2004 Jan; 43(1):62-72. PubMed ID: 12890861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.
    Bansback NJ; Brennan A; Ghatnekar O
    Ann Rheum Dis; 2005 Jul; 64(7):995-1002. PubMed ID: 15550533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis: Observational Data from Southern Sweden.
    Wallman JK; Eriksson JK; Nilsson JÅ; Olofsson T; Kristensen LE; Neovius M; Geborek P
    J Rheumatol; 2016 Jul; 43(7):1292-9. PubMed ID: 27252420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shared care or nurse consultations as an alternative to rheumatologist follow-up for rheumatoid arthritis (RA) outpatients with stable low disease-activity RA: cost-effectiveness based on a 2-year randomized trial.
    Sørensen J; Primdahl J; Horn HC; Hørslev-Petersen K
    Scand J Rheumatol; 2015; 44(1):13-21. PubMed ID: 25380077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain.
    Carreño A; Fernández I; Badia X; Varela C; Roset M
    Value Health; 2011 Jan; 14(1):192-200. PubMed ID: 21211502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data.
    Kim HL; Kim D; Jang EJ; Lee MY; Song HJ; Park SY; Cho SK; Sung YK; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim J; Kim SK; Kim TH; Kim TJ; Koh E; Lee H; Lee HS; Lee J; Lee SS; Lee SW; Park SH; Shim SC; Yoo DH; Yoon BY; Bae SC; Lee EK
    Rheumatol Int; 2016 Apr; 36(4):505-13. PubMed ID: 26849891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
    Lindgren P; Geborek P; Kobelt G
    Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France.
    Saraux A; Gossec L; Goupille P; Bregman B; Boccard E; Dupont D; Beresniak A
    Rheumatology (Oxford); 2010 Apr; 49(4):733-40. PubMed ID: 20081224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L; Pope JE; Payne M
    J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis.
    Marra CA; Woolcott JC; Kopec JA; Shojania K; Offer R; Brazier JE; Esdaile JM; Anis AH
    Soc Sci Med; 2005 Apr; 60(7):1571-82. PubMed ID: 15652688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate.
    Stevenson MD; Wailoo AJ; Tosh JC; Hernandez-Alava M; Gibson LA; Stevens JW; Archer RJ; Simpson EL; Hock ES; Young A; Scott DL
    J Rheumatol; 2017 Jul; 44(7):973-980. PubMed ID: 28202743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden.
    Lekander I; Borgström F; Svarvar P; Ljung T; Carli C; van Vollenhoven RF
    Int J Technol Assess Health Care; 2010 Jan; 26(1):54-61. PubMed ID: 20059781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analyses of targeted immunomodulators in rheumatoid arthritis: systematic review.
    Sussman M; Tao C; Patel P; Tundia N; Clewell J; Menzin J
    J Med Econ; 2020 Jun; 23(6):610-623. PubMed ID: 31971039
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of utility measures and their relationship with other health status measures in 1041 patients with rheumatoid arthritis.
    Lillegraven S; Kristiansen IS; Kvien TK
    Ann Rheum Dis; 2010 Oct; 69(10):1762-7. PubMed ID: 20448285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.